Related Experiment Video
Updated: Jul 5, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Fluvastatin treatment and withdrawal: effects on endothelial function.
Sabine Westphal1, Claudia Abletshauser, Claus Luley
1Institute of Clinical Chemistry and Pathobiochemistry, Magdeburg University Hospital. Sabine.Westphal@Medizin.Uni-Magdeburg.de
Angiology
|April 17, 2008
Summary
Fluvastatin improves endothelial function, particularly in patients with low baseline values. However, this benefit is temporary, with function returning to baseline levels shortly after discontinuing the medication.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Biology
Background:
- Statins, including fluvastatin, are known to lower lipids.
- Fluvastatin has demonstrated protective effects on endothelial function.
- The impact of different fluvastatin formulations on endothelial function and the duration of these effects require further investigation.
Purpose of the Study:
- To compare the effects of extended-release and immediate-release fluvastatin on endothelial function.
- To assess endothelial function after fluvastatin treatment discontinuation.
- To identify patient subgroups that may benefit most from fluvastatin's effects on endothelial function.
Main Methods:
- A randomized controlled trial involving 27 patients.
- Patients received either 80 mg extended-release fluvastatin daily, 40 mg immediate-release fluvastatin twice daily, or placebo for 5 weeks.
- Flow-mediated dilation (FMD) and fasting lipids were measured at baseline, post-treatment, and 24 hours after treatment cessation.
Main Results:
- Both fluvastatin formulations significantly improved FMD (P < .037 for extended-release, P < .001 for immediate-release).
- Improvements in FMD were more pronounced in patients with lower baseline FMD (<5%).
- FMD returned to baseline levels 24 hours after discontinuation of both fluvastatin formulations (P < .001).
Conclusions:
- Fluvastatin enhances endothelial function, with a notable effect in patients exhibiting impaired baseline vasodilation.
- The positive effects of fluvastatin on endothelial function are transient and do not persist after treatment cessation.
- These findings suggest that continuous fluvastatin therapy is necessary to maintain improvements in endothelial function.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.